Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Laromestrocel

Source date not recordedAnalyse record ↗

Allogeneic stromal-cell therapy studied in pediatric heart disease, Alzheimer’s disease and aging-related frailty; the pediatric ELPIS II Phase 2b trial missed its primary endpoint.

Modality
allogeneic bone-marrow-derived mesenchymal stromal cell product
Availability (US)
Phase 2b ELPIS II follow-up Active, not recruiting; company evaluating next development steps and funding options
Biomarkers
right-ventricular ejection fraction; transplant-free survival; hospitalization; adverse events; physical-function measures
Hallmark targeted
stem-cell function, tissue repair, regenerative signaling, chronic inflammation
Kind
investigational cell therapy
Clinical trials
NCT04925024 — Phase 2, Active, not recruiting on June 25, 2025 registry update; NCT02982915 — Phase 1/Phase 2 aging-frailty study Completed